TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33516464

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of Bupleurum falcatum L saikosaponins (80 mg/kg of diet)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no dietary supplementation of saikosaponins)
Number of subjects: 480
Study: 32057375

Group type: EXPERIMENTAL
Intervention: Women with PAD
Number of subjects: 13885
Study: 33557610

Group type: EXPERIMENTAL
Intervention: Nasoalveolar Molding (NAM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Computer-Aided Design NAM (CAD/NAM)
Number of subjects: 30
Study: 33462904

Group type: EXPERIMENTAL
Intervention: Usual care plus application of uncoated paper on the sacral area for 5 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 135
Study: 33036662

Group type: EXPERIMENTAL
Intervention: Ginger-based herbal tablets (Vomigone ®) at a dose of 1000 mg three times a day for seven days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 along with Vomigone-like placebo tablets
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ginger-based herbal tablets (Vomigone ®)
Number of subjects: 84
Study: 35984871

Group type: EXPERIMENTAL
Intervention: Ashwagandha (700 mg daily, full spectrum extract of ASH root)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study: 33509667

Group type: EXPERIMENTAL
Intervention: 21.6 g/day Biotis™ GOS (containing 15.0 g/day GOS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32553820

Group type: EXPERIMENTAL
Intervention: HEARTBiT blood test for excluding acute cellular rejection (ACR)
Number of subjects: 1622

Group type: COMPARATOR
Intervention: AlloMap (CareDx, Brisbane, CA)
Number of subjects: 1622
Study: 32985777

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for health anxiety (CBT-HA)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444
Study: 33004018

Group type: EXPERIMENTAL
Intervention: EFIC enrollment
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Disclosure of positive PAMPer study outcome
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Disclosure of hypothetical negative study outcome
Number of subjects: 169
Study: 35213904

Group type: EXPERIMENTAL
Intervention: Early treatment (rectal ibuprofen or intravenous acetaminophen)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 208
Study: 32677051

Group type: EXPERIMENTAL
Intervention: Ketamine (single intravenous dose)
Number of subjects: 68
Study: 32216168

Group type: EXPERIMENTAL
Intervention: Dissolvable nasal dressing (foam) applied to the olfactory cleft
Number of subjects: 30
Study: 36267766

Group type: EXPERIMENTAL
Intervention: Kai Hou Jian (2.5 mL via transoral atomization twice daily for 1 week)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Budesonide (1 mg nebulization twice daily for 1 week)
Number of subjects: 86
Study: 34004226

Group type: EXPERIMENTAL
Intervention: S. salivarius DB‐B5 at 10 billion CFU/day for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35054027

Group type: EXPERIMENTAL
Intervention: ANI-guided remifentanil administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard management of remifentanil
Number of subjects: 80
Study: 32945735

Group type: EXPERIMENTAL
Intervention: Dried cranberry powder (500 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 98
Study: 33895361

Group type: EXPERIMENTAL
Intervention: Switch to peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Number of subjects: 253

Group type: COMPARATOR
Intervention: Continued nucleoside analogues (controls)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Switch to peginterferon-alpha2b
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Add-on peginterferon-alpha2b
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Peginterferon treatment
Number of subjects: 253
Study: 33276811

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (α‐interferon, lopinavir/ritonavir, chloroquine, ribavirin, or arbidol)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Antiviral therapy alone (same scheme as in stage 1)
Number of subjects: 43
Study: 36097674

Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA injections after a 1-month oral lead-in
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA injections
Number of subjects: 102
Study: 32152512

Group type: EXPERIMENTAL
Intervention: Intermittent tube feeding
Number of subjects: 78

Group type: COMPARATOR
Intervention: Continuous tube feeding
Number of subjects: 78
Study: 36433813

Group type: EXPERIMENTAL
Intervention: Video counseling (VC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional counseling (CC)
Number of subjects: 30
Study: 33340084

Group type: EXPERIMENTAL
Intervention: Fixed implant‐supported prostheses (FP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Removable implant‐supported prostheses (RP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional total prostheses (CP)
Number of subjects: 96
Study: 32536023

Group type: EXPERIMENTAL
Intervention: 10 g 2’FL/LNnT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 g 2’FL/LNnT
Number of subjects: 60
Study: 36301546

Group type: EXPERIMENTAL
Intervention: Mentorship and portable rent subsidies
Number of subjects: 24

Group type: COMPARATOR
Intervention: No mentorship and portable rent subsidies
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Informal mentors
Number of subjects: 24
Study: 33904615

Group type: EXPERIMENTAL
Intervention: Positive feedback (self-esteem boost)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 0
Study: 33089598

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg bid
Number of subjects: 207

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg bid
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Eradication-successful patients
Number of subjects: 207

Group type: COMPARATOR
Intervention: Eradication-failed patients
Number of subjects: 207
Study: 32708343

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) in endoscopic assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnostic systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AI systems
Number of subjects: 0
Study: 35321918

Group type: EXPERIMENTAL
Intervention: Prone positioning (lying on stomach)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard of care (no instruction to adopt prone position)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 248
Study: 34579785

Group type: EXPERIMENTAL
Intervention: ED-dispensing of ICS with home and school supervision
Number of subjects: 13

Group type: COMPARATOR
Intervention: ED-dispensing of ICS with home supervision
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall participant retention
Number of subjects: 13
Study: 36229147

Group type: EXPERIMENTAL
Intervention: ECCE programme
Number of subjects: 3240
Study: 33910549

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Children (MBCT-C)
Number of subjects: 10
Study: 32387091

Group type: EXPERIMENTAL
Intervention: apoB
Number of subjects: 0

Group type: COMPARATOR
Intervention: LDL-C/non-HDL-C
Number of subjects: 0
Study: 36170581

Group type: EXPERIMENTAL
Intervention: Traditional physical therapy combined with pulsed local cryotherapy three times per week for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional physical therapy three times per week for 12 weeks
Number of subjects: 40
Study: 34977251

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 60
Study: 34636433

Group type: EXPERIMENTAL
Intervention: High-volume centers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-volume centers
Number of subjects: 0
Study: 34939887

Group type: EXPERIMENTAL
Intervention: Physical Component Summary (PCS) score at 12 months
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Change in PCS score between 6 and 12 months
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cohen's method for estimating MCID from PCS score distribution
Number of subjects: 400
Study: 35058605

Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 43
Study: 33913678

Group type: EXPERIMENTAL
Intervention: PRD-guided remifentanil administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard anaesthesia care (control)
Number of subjects: 100
Study: 36355371

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin 2 (LD-IL-2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32513260

Group type: EXPERIMENTAL
Intervention: Antioxidant dressing therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 0
Study: 33303279

Group type: EXPERIMENTAL
Intervention: Automatic lancet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual lancet
Number of subjects: 60
Study: 32850394

Group type: EXPERIMENTAL
Intervention: Weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 3-weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Weekly TPF
Number of subjects: 82

Group type: COMPARATOR
Intervention: 3-weekly TPF
Number of subjects: 82
Study: 35379618

Group type: EXPERIMENTAL
Intervention: DRE with daytime compression garment during exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DRE with adjustable compression wrap during exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 34098931

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Live Demonstration (LD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both LD and FC
Number of subjects: 40
Study: 32955273

Group type: EXPERIMENTAL
Intervention: REDI preschool intervention
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 294
Study: 34627665

Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 98
Study: 32663139

Group type: EXPERIMENTAL
Intervention: LowSalt4Life intervention (App group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No App group (usual dietary advice)
Number of subjects: 50
Study: 34346833

Group type: EXPERIMENTAL
Intervention: Vaccination at baseline (intervention)
Number of subjects: 11391

Group type: COMPARATOR
Intervention: Control group (vaccination at 12 months)
Number of subjects: 11391
Study: 33185028

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (q.d.) with a 7-day lead-in at 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brigatinib 90 mg once daily (q.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brigatinib (general exposure)
Number of subjects: 0
Study: 32962509

Group type: EXPERIMENTAL
Intervention: Slow speed condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All speed conditions
Number of subjects: 21
Study: 33214444

Group type: EXPERIMENTAL
Intervention: Surgeons influenced by the belief that pursuing surgery gives the patient or family time to cope with the patient's condition
Number of subjects: 2161

Group type: COMPARATOR
Intervention: Surgeons whose decisions were influenced by time required to discuss non-operative treatments
Number of subjects: 2161

Group type: COMPARATOR
Intervention: Surgeons whose decisions were influenced by the consulting intensivists' endorsement of operative intervention
Number of subjects: 2161
Study: 36432562

Group type: EXPERIMENTAL
Intervention: H2-producing milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33417414

Group type: EXPERIMENTAL
Intervention: Carotid Intraplaque Hemorrhage (IPH) in patients with RAO
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (patients without prior ischemic event)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carotid IPH
Number of subjects: 14
Study: 32449335

Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conventional general anesthesia with extra administration of intraoperative magnesium sulphate
Number of subjects: 80
Study: 35704292

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (50 mg/kg every 6 hours for up to 96 hours)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study: 34864925

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) 120/960 mg
Number of subjects: 748

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500/75 mg
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 748
Study: 32986498

Group type: EXPERIMENTAL
Intervention: Venetoclax plus Rituximab (VenR) for 2 years
Number of subjects: 389

Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab (BR) for 6 cycles
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: VenR with undetectable minimal residual disease (uMRD) at end of combination therapy (EOCT)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: VenR followed by ibrutinib as first therapy after progression
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: VenR followed by venetoclax-based regimen
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: VenR
Number of subjects: 389
Study: 34994838

Group type: EXPERIMENTAL
Intervention: 1% Patent Blue Dye injection in the upper outer quadrant of the breast (validated by radioactive nanocolloid)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Classic retro-areolar patent blue injection
Number of subjects: 279
Study: 33926211

Group type: EXPERIMENTAL
Intervention: Advice leaflet
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Advice video
Number of subjects: 116

Group type: COMPARATOR
Intervention: Face-to-face therapy
Number of subjects: 116
Study: 32265291

Group type: EXPERIMENTAL
Intervention: Inspiratory load intensity 20% of maximum inspiratory pressure
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inspiratory load intensity 40% of maximum inspiratory pressure
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nasal interface
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral interface
Number of subjects: 29
Study: 34479838

Group type: EXPERIMENTAL
Intervention: apalutamide (240 mg/d)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1207
Study: 32662379

Group type: EXPERIMENTAL
Intervention: Maternal weight at enrollment (12-20 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Maternal weight at 36 weeks
Number of subjects: 46
Study: 33055173

Group type: EXPERIMENTAL
Intervention: Vorinostat plus Sirolimus (V+S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vorinostat plus Everolimus (V+E)
Number of subjects: 40
Study: 35212402

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5 ml of 5%)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 μg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream and misoprostol
Number of subjects: 210
Study: 33894061

Group type: EXPERIMENTAL
Intervention: OPEN‐DRUG+INST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPEN‐DRUG+INST+COND
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLAC+INST+COND
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIDDEN‐DRUG
Number of subjects: 0
Study: 32194214

Group type: EXPERIMENTAL
Intervention: Asthma Outcome Expectation‐self‐efficacy subscale (AOE‐SE)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Asthma Management Index‐self‐efficacy subscale (AMI‐SE)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Asthma Self‐Efficacy scale (ASE)
Number of subjects: 371
Study: 35353961

Group type: EXPERIMENTAL
Intervention: Mini-slings
Number of subjects: 596

Group type: COMPARATOR
Intervention: Midurethral slings
Number of subjects: 596
Study: 34684557

Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (SP) supplementation (50 mg·kg‐1 of fat‐free mass/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32367882

Group type: EXPERIMENTAL
Intervention: Surface coated with G‐Coat Plus (GC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Uncoated
Number of subjects: 70
Study: 36275396

Group type: EXPERIMENTAL
Intervention: Group BR (20 ml of 0.33% ropivacaine plus 1 mg butorphanol)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group BR
Number of subjects: 74

Group type: COMPARATOR
Intervention: Group R (20 ml of 0.33% ropivacaine plus 1 ml normal saline)
Number of subjects: 74
Study: 34125374

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Radiation and chemotherapy at diagnosis
Number of subjects: 159
Study: 34597436

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 35
Study: 32985910

Group type: EXPERIMENTAL
Intervention: Higher levels of HDL-C
Number of subjects: 275

Group type: COMPARATOR
Intervention: Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG)
Number of subjects: 275
Study: 35726856

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-True)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-False)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.3 g·kg‐1 dextrose placebo (PLC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: nothing (CON)
Number of subjects: 15
Study: 32243248

Group type: EXPERIMENTAL
Intervention: Activated charcoal‐based powder
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1450‐ppm F toothpaste (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 45
Study: 35331337

Group type: EXPERIMENTAL
Intervention: For Our Children's Sake (FOCS) intervention
Number of subjects: 35
Study: 33661967

Group type: EXPERIMENTAL
Intervention: 10% topical diclofenac
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 32092439

Group type: EXPERIMENTAL
Intervention: Individually-targeted weekly coupons (valued up to $10) with brief nutrition education for 13 weeks
Number of subjects: 224

Group type: COMPARATOR
Intervention: Weekly untargeted nutrition education and occasional generic coupons
Number of subjects: 224
Study: 32762784

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Traditional Lecture‐based Classroom (TLC)
Number of subjects: 103
Study: 32026820

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n=35; technology-based home exercise program using an iPad application)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n=35)
Number of subjects: 69

Group type: COMPARATOR
Intervention: In-person outpatient physiotherapy (control group n=35)
Number of subjects: 69
Study: 36227309

Group type: EXPERIMENTAL
Intervention: Modified clinical reminder intervention (N = 44 teams)
Number of subjects: 28441

Group type: COMPARATOR
Intervention: Status quo (N = 40 teams)
Number of subjects: 28441
Study: 34183350

Group type: EXPERIMENTAL
Intervention: Digital cognitive-behavioural therapy for insomnia (dCBT-I)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Patient education about insomnia (PE)
Number of subjects: 800
Study: 35218300

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART) offered through trial clinics in intervention clusters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving ART according to national guidelines
Number of subjects: 0
Study: 32012085

Group type: EXPERIMENTAL
Intervention: mHealth interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth evaluation
Number of subjects: 0
Study: 33307388

Group type: EXPERIMENTAL
Intervention: RFD-RFL index scores
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Endorsing more RFD relative to RFL
Number of subjects: 167
Study: 32223612

Group type: EXPERIMENTAL
Intervention: Music plus relaxation suggestions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Music alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 66
Study: 35324053

Group type: COMPARATOR
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Porcine-Derived Collagen Matrix (PDCM)
Number of subjects: 45
Study: 33347771

Group type: EXPERIMENTAL
Intervention: Pollen count rises past medium or higher thresholds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pollen count rises past established thresholds
Number of subjects: 0
Study: 33420853

Group type: EXPERIMENTAL
Intervention: Pulsed non-thermal atmospheric pressure nitrogen plasma
Number of subjects: 25

Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 25
Study: 35613846

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 33931570

Group type: EXPERIMENTAL
Intervention: FESCE-based protocolised rehabilitation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 150